Kim N Chi, Steven M Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J Hotte, David T Laidley, Fred Saad
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177 Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177 Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice...
March 7, 2024: Current Oncology